Latham & Watkins Advises Baird Capital in Saranas’ US$12.8 Million Series B Financing

An emerging companies team advises the lead investor in the financing.

July 22, 2021

Saranas, Inc., a privately held medical device company focusing on improving patient outcomes through early detection and monitoring of internal bleeding complications, has announced a US$12.8 million Series B investment led by Baird Capital, the venture capital and global private equity arm of Baird. Baird Capital was joined in the investment by Austin, Texas-based S3 Ventures.

Latham & Watkins LLP represents Baird Capital in the transaction with an emerging companies team led by Boston partner Evan Smith, with New York associate Teddy Ellison. Boston partner Hans Brigham provided additional advice on corporate matters.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.